Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD Journal Article

Local Library Link: Find It @ Loyola

Authors: Markossian, T; Burge, N.; Ling, B; Schneider, J; Pacold, I.; Bansal, V.; Leehey, D.; Stroupe, K; Chang, A; Kramer, H
Article Title: Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD
Abstract: Adults with chronic kidney disease (CKD) are at heightened risk for dying of cardiovascular disease. Results from randomized clinical trials of statin drugs versus placebo demonstrate that statin drugs or statin plus ezetimibe reduce the absolute risk for coronary heart disease and mortality among adults with non-dialysis-dependent CKD. The Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline for lipid management in CKD recommends that adults 50 years or older with non-dialysis-dependent CKD be treated with a statin or statin plus ezetimibe regardless of low-density lipoprotein cholesterol levels. However, at least 9 guidelines published during the last 5 years address lipid management for primary and secondary prevention of atherosclerotic cardiovascular disease, and not all guidelines address the utility of lipid-lowering therapy in adults with CKD. Because most patients with CKD receive most of their clinical care from non-nephrologists, differences in recommendations for lipid-lowering therapy for cardiovascular disease prevention may negatively affect the clinical care of adults with CKD and cause confusion for both patients and providers. This review addresses the identification and management of lipid levels in patients with CKD and discusses the existing controversies regarding testing and treatment of lipid levels in the CKD population.
Journal Title: American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation
ISSN: 1523-6838; 0272-6386
Publisher: National Kidney Foundation, Inc  
Date Published: 2016
Language: ENG
DOI/URL:

S0272-6386(16)00022-6
Notes: LR: 20160306; CI: Copyright (c) 2016; JID: 8110075; OTO: NOTNLM; 2015/08/17 [received]; 2015/12/07 [accepted]; aheadofprint